[Combination chemotherapy for acute myeloid leukemia].
Combination chemotherapy with Ara-C and anthracycline anti-leukemia drugs is a standard therapeutics for acute myeloid leukemia (AML) and results in a high rate of complete remission (CR). Several salvage therapies have been established for relapse/refractory AML cases. In addition, a trial of the combination of chemotherapy with gemtuzumab ozogamicin for poor-risk AML is ongoing. The development of a new strategy including combination of conventional anti-leukemia drugs with molecule-targeting reagents might be needed to increase CR rate and cure rates by combination chemotherapy. Development of therapeutics to eradicate leukemia stem cells is also of important for increasing the cure rate of AML.
Nagai
Tadashi
T
Division of Hematology, Department of Medicine, Jichi Medical University.
D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000008:administration & dosage; D018943:Anthracyclines / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012074:Remission Induction; D016879:Salvage Therapy
D000617:Aminoglycosides; D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003561:Cytarabine; D000079982:Gemtuzumab